High-Dose Topical Bevacizumab for Corneal Neovascularization

Publisher： Karger

E-ISSN： 1423-0313|92|5-6|310-314

ISSN： 0031-7012

Source： Pharmacology, Vol.92, Iss.5-6, 2013-12, pp. : 310-314

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model

By Kuo Chien-Neng   Chen Chung-Yi   Chen San-Ni   Yang Lin-Cheng   Lai Li-Ju   Lai Chien-Hsiung   Chen Miao-Fen   Hung Chia-Hui   Chen Ching-Hsein  

International Journal of Molecular Sciences, Vol. 14, Iss. 4, 2013-04 ,pp. : 8291-8305

MDPI

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

High-Dose Ibuprofen in Cystic Fibrosis

By Lands Larry C.   Dauletbaev Nurlan  

Pharmaceuticals, Vol. 3, Iss. 7, 2010-07 ,pp. : 2213-2224

MDPI

Access to resources Recommend Favorite

Extravasation of High‐Dose Methotrexate A Case about Nothing

By  

The Australian Journal of Hospital Pharmacy, Vol. 28, Iss. 6, 1998-12 ,pp. : 430-431

John Wiley & Sons Inc

Access to resources Recommend Favorite

Topical Bevacizumab for Neovascular Glaucoma: A Pilot Study

By  

Pharmacology, Vol. 93, Iss. 3-4, 2014-02 ,pp. : 108-112

Karger

Access to resources Recommend Favorite